It was previously found that overexpression of SUMO, which occurs in conditions such as brain ischemia and hypoxia, could increase cell survival, whereas in contrast, the knockdown of SUMO expression has been shown to be toxic to cells and is associated with TGFβ1 in resistant glioma cells[48]. The gene discussed is TGFB1; the disease is central nervous system cancer.